The important molecular markers on chromosome 17 and their clinical impact in breast cancer

International Journal of Molecular Sciences

Volumn 12, Issue 9, 2011, Pages 5672-5683

  Zhang, Wei ^a   Yu, Yingyan ^b  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Biomarkers; Breast cancer; Chromosome 17

Indexed keywords

ANTHRACYCLINE; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; TUMOR MARKER; ANTINEOPLASTIC AGENT;

BREAST CANCER; BREAST CANCER 1 GENE; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CHROMOSOME 17; DNA TOPOISOMERASE II ALPHA; DRUG EFFICACY; GENE FUNCTION; GENE LOCATION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC DATABASE; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 GENE; HYPERMETHYLATED IN CANCER 1 GENE; METASTASIS; OVERALL SURVIVAL; P53 GENE; RAD52 MOTIF 1 GENE; REVIEW; TUMOR SUPPRESSOR GENE; BREAST NEOPLASMS; CHROMOSOME ABERRATION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; PATHOLOGY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; TUMOR MARKERS, BIOLOGICAL;

EID: 80053198864     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms12095672     Document Type: Review

References (60)

1. Reinholz, M.M.; Bruzek, A.K.; Visscher, D.W.; Lingle, W.L.; Schroeder, M.J.; Perez, E.A.; Jenkins, R.B. Breast cancer and aneusomy 17: Implications for carcinogenesis and therapeutic response. Lancet Oncol. 2009, 10, 267-277.
2. Ross, J.S.; McKenna, B.J. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest. 2001, 19, 554-568.
3. Brien, T.P.; Depowski, P.L.; Sheehan, C.E.; Ross, J.S.; McKenna, B.J. Prognostic factors in gastric cancer. Modern Pathol. 1998, 11, 870-877.
4. Sharif, S.; Ramanathan, R.K.; Potter, D.; Cieply, K.; Krasinskas, A.M. HER2 gene amplification and chromosome 17 copy number do not predict survival of patients with resected pancreatic adenocarcinoma. Digest. Dis. Sci. 2008, 53, 3026-3032.
5. Shafizadeh, N.; Grenert, J.P.; Sahai, V.; Kakar, S. Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder. Hum. Pathol. 2010, 41, 485-492.
6. Rosenthal, S.I.; Depowski, P.L.; Sheehan, C.E.; Ross, J.S. Comparison of HER-2/neu oncogene amplification detected by fluorescence in situ hybridization in lobular and ductal breast cancer. Appl. Immunohistochem. Mol. Morphol. 2002, 10, 40-46.
7. Bedard, P.L.; Piccart-Gebhart, M.J. Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer. Clin. Breast Cancer 2008, 8, S157-S165.
8. Yin, W.; Jiang, Y.; Shen, Z.; Shao, Z.; Lu, J. Trastuzumab in the adjuvant treatment of her2-positive early breast cancer patients: A meta-analysis of published randomized controlled trials. PLoS One 2011, 6. doi:10.1371/journal.pone.0021030.
9. Wolff, A.C.; Hammond, M.E.; Schwartz, J.N.; Hagerty, K.L.; Allred, D.C.; Cote, R.J.; Dowsett, M.; Fitzgibbons, P.L.; Hanna, W.M.; Langer, A.; et al. American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch. Pathol. Lab. Med. 2007, 131, 18-43.
10. Chia, S.; Norris, B.; Speers, C.; Cheang, M.; Gilks, B.; Gown, A.M.; Huntsman, D.; Olivotto, I.A.; Nielsen, T.O.; Gelmon, K. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J. Clin. Oncol. 2008, 26, 5697-5704.
11. Guiu, S.; Liegard, M.; Favier, L.; van Praagh, I.; Largillier, R.; Weber, B.; Coeffic, D.; Moreau, L.; Priou, F.; Campone, M.; et al. Long-term follow-up of her2-overexpressing stage ii oriii breast cancer treated by anthracycline-free neoadjuvant chemotherapy. Ann. Oncol. 2011, 22, 321-328.
12. Wolff, A.C.; Hammond, M.E.; Schwartz, J.N.; Hagerty, K.L.; Allred, D.C.; Cote, R.J.; Dowsett, M.; Fitzgibbons, P.L.; Hanna, W.M.; Langer, A.; et al. American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007, 25, 118-145.
13. Carlson, R.W.; Moench, S.J.; Hammond, M.E.; Perez, E.A.; Burstein, H.J.; Allred, D.C.; Vogel, C.L.; Goldstein, L.J.; Somlo, G.; Gradishar,; W.J. et al. Her2 testing in breast cancer: Nccn task force report and recommendations. J. Natl. Compr. Cancer Netw. 2006, 4, S1-S22. quiz S23-S24.
14. Bouchalova, K.; Trojanec, R.; Kolar, Z.; Cwiertka, K.; Cernakova, I.; Mihal, V.; Hajduch, M. Analysis of erbb2 and top2a gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer. Neoplasma 2006, 53, 393-401.
15. Salido, M.; Tusquets, I.; Corominas, J.M.; Suarez, M.; Espinet, B.; Corzo, C.; Bellet, M.; Fabregat, X.; Serrano, S.; Sole, F. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of erbb2: A study of 175 cases using fluorescence in situ hybridization and immunohistochemistry. Breast Cancer Res. 2005, 7, R267-R273.
16. Zhu, X.; Lu, Y.; Lu, H.; Yang, W.; Tu, X.; Cai, X.; Zhou, X. Genetic alterations and protein expression of her2 and chromosome 17 polysomy in breast cancer. Hum. Pathol. 2011, doi:10.1016/j.humpath.2010.04.023.
17. Moelans, C.B.; de Weger, R.A.; van Diest, P.J. Absence of chromosome 17 polysomy in breast cancer: Analysis by cep17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification. Breast Cancer Res. Treat. 2010, 120, 1-7.
18. Shah, S.S.; Wang, Y.; Tull, J.; Zhang, S. Effect of high copy number of her2 associated with polysomy 17 on her2 protein expression in invasive breast carcinoma. Diagn. Mol. Pathol. 2009, 18, 30-33.
19. Downey, L.; Livingston, R.B.; Koehler, M.; Arbushites, M.; Williams, L.; Santiago, A.; Guzman, R.; Villalobos, I.; Di Leo, A.; Press, M.F. Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer. Clin. Cancer Res. 2010, 16, 1281-1288.
20. Slamon, D.J.; Press, M.F. Alterations in the top2a and her2 genes: Association with adjuvant anthracycline sensitivity in human breast cancers. J. Natl. Cancer Inst. 2009, 101, 615-618.
21. O'Malley, F.P.; Chia, S.; Tu, D.; Shepherd, L.E.; Levine, M.N.; Bramwell, V.H.; Andrulis, I.L.; Pritchard, K.I. Topoisomerase ii alpha and responsiveness of breast cancer to adjuvant chemotherapy. J. Natl. Cancer Inst. 2009, 101, 644-650.
22. Orlando, L.; del Curto, B.; Gandini, S.; Ghisini, R.; Pietri, E.; Torrisi, R.; Balduzzi, A.; Cardillo, A.; Dellapasqua, S.; Veronesi, P.; et al. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer. Breast 2008, 17, 506-511.
23. Miyoshi, Y.; Kurosumi, M.; Kurebayashi, J.; Matsuura, N.; Takahashi, M.; Tokunaga, E.; Egawa, C.; Masuda, N.; Kono, S.; Morimoto, K.; et al. Predictive factors for anthracycline-based chemotherapy for human breast cancer. Breast Cancer 2010, 17, 103-109.
24. McGrogan, B.T.; Gilmartin, B.; Carney, D.N.; McCann, A. Taxanes, microtubules and chemoresistant breast cancer. Biochim. Biophys. Acta. 2008, 1785, 96-132.
25. Pusztai, L. Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. Ann. Oncol. 2007, 18, xii15-xii20.
26. Andre, F.; Hatzis, C.; Anderson, K.; Sotiriou, C.; Mazouni, C.; Mejia, J.; Wang, B.; Hortobagyi, G.N.; Symmans, W.F.; Pusztai, L. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin. Cancer Res. 2007, 13, 2061-2067.
27. Tanaka, S.; Nohara, T.; Iwamoto, M.; Sumiyoshi, K.; Kimura, K.; Takahashi, Y.; Tanigawa, N. Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer. Cancer Chemother. Pharmacol. 2009, 64, 341-346.
28. Milne, G.T.; Ho, T.; Weaver, D.T. Modulation of saccharomyces cerevisiae DNA double-strand break repair by srs2 and rad51. Genetics 1995, 139, 1189-1199.
29. Hamimes, S.; Arakawa, H.; Stasiak, A.Z.; Kierzek, A.M.; Hirano, S.; Yang, Y.G.; Takata, M.; Stasiak, A.; Buerstedde, J.M.; van Dyck, E. RDM1, a novel RNA recognition motif (RRM)-containing protein involved in the cell response to cisplatin in vertebrates. J. Biol. Chem. 2005, 280, 9225-9235.
30. Hamimes, S.; Bourgeon, D.; Stasiak, A.Z.; Stasiak, A.; Van Dyck, E. Nucleic acid-binding properties of the RRM-containing protein RDM1. Biochem. Biophys. Res. Commun. 2006, 344, 87-94.
31. Messaoudi, L.; Yang, Y.G.; Kinomura, A.; Stavreva, D.A.; Yan, G.; Bortolin-Cavaille, M.L.; Arakawa, H.; Buerstedde, J.M.; Hainaut, P.; Cavaille, J.; et al. Subcellular distribution of human rdm1 protein isoforms and their nucleolar accumulation in response to heat shock and proteotoxic stress. Nucleic Acids Res. 2007, 35, 6571-6587.
32. Abe, H.; Wada, M.; Kohno, K.; Kuwano, M. Altered drug sensitivities to anticancer agents in radiation-sensitive DNA repair deficient yeast mutants. Anticancer Res. 1994, 14, 1807-1810.
33. Yamaguchi-Iwai, Y.; Sonoda, E.; Buerstedde, J.M.; Bezzubova, O.; Morrison, C.; Takata, M.; Shinohara, A.; Takeda, S. Homologous recombination, but not DNA repair, is reduced in vertebrate cells deficient in rad52. Mol. Cell. Biol. 1998, 18, 6430-6435.
34. van Hille, B.; Clerc, X.; Creighton, A.M.; Hill, B.T. Differential expression of topoisomerase i and rad52 protein in yeast reveals new facets of the mechanism of action of bisdioxopiperazine compounds. Br. J. Cancer 1999, 81, 800-807.
35. Miki, Y.; Swensen, J.; Shattuck-Eidens, D.; Futreal, P.A.; Harshman, K.; Tavtigian, S.; Liu, Q.; Cochran, C.; Bennett, L.M.; Ding, W.; et al. A strong candidate for the breast and ovarian cancer susceptibility gene brca1. Science 1994, 266, 66-71.
36. Rhiem, K.; Todt, U.; Wappenschmidt, B.; Klein, A.; Wardelmann, E.; Schmutzler, R.K. Sporadic breast carcinomas with somatic brca1 gene deletions share genotype/phenotype features with familial breast carcinomas. Anticancer Res. 2010, 30, 3445-3449.
37. Tassone, P.; di Martino, M.T.; Ventura, M.; Pietragalla, A.; Cucinotto, I.; Calimeri, T.; Bulotta, A.; Neri, P.; Caraglia, M.; Tagliaferri, P. Loss of brca1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo. Cancer Biol. Ther. 2009, 8, 648-653.
38. Liu, X.; Holstege, H.; van der Gulden, H.; Treur-Mulder, M.; Zevenhoven, J.; Velds, A.; Kerkhoven, R.M.; van Vliet, M.H.; Wessels, L.F.; Peterse, J.L.; et al. Somatic loss of brca1 and p53 in mice induces mammary tumors with features of human brca1-mutated basal-like breast cancer. Proc. Natl. Acad. Sci. USA 2007, 104, 12111-12116.
39. Birgisdottir, V.; Stefansson, O.A.; Bodvarsdottir, S.K.; Hilmarsdottir, H.; Jonasson, J.G.; Eyfjord, J.E. Epigenetic silencing and deletion of the brca1 gene in sporadic breast cancer. Breast Cancer Res. 2006, 8, R38.
40. Wei, M.; Grushko, T.A.; Dignam, J.; Hagos, F.; Nanda, R.; Sveen, L.; Xu, J.; Fackenthal, J.; Tretiakova, M.; Das, S.; Olopade, O.I. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res. 2005, 65, 10692-10699.
41. Lo, Y.L.; Yu, J.C.; Huang, C.S.; Tseng, S.L.; Chang, T.M.; Chang, K.J.; Wu, C.W.; Shen, C.Y. Allelic loss of the BRCA1 and BRCA2 genes and other regions on 17q and 13q in breast cancer among women from Taiwan (area of low incidence but early onset). Int. J. Cancer 1998, 79, 580-587.
42. Soussi, T. The p53 tumor suppressor gene: From molecular biology to clinical investigation. Ann. NY Acad. Sci. 2000, 910, 121-139.
43. Rigatti, M.J.; Verma, R.; Belinsky, G.S.; Rosenberg, D.W.; Giardina, C. Pharmacological inhibition of mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells. Mol. Carcinog. 2011, doi:10.1002/mc.20795.
44. Tovar, C.; Rosinski, J.; Filipovic, Z.; Higgins, B.; Kolinsky, K.; Hilton, H.; Zhao, X.; Vu, B.T.; Qing, W.; Packman, K.; et al. Small-molecule mdm2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy. Proc. Natl. Acad. Sci. USA 2006, 103, 1888-1893.
45. Guerardel, C.; Deltour, S.; Pinte, S.; Monte, D.; Begue, A.; Godwin, A.K.; Leprince, D. Identification in the human candidate tumor suppressor gene HIC-1 of a new major alternative TATA-less promoter positively regulated by p53. J. Biol. Chem. 2001, 276, 3078-3089.
46. Nishida, N.; Nagasaka, T.; Nishimura, T.; Ikai, I.; Boland, C.R.; Goel, A. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology 2008, 47, 908-918.
47. Oh, B.K.; Kim, H.; Park, H.J.; Shim, Y.H.; Choi, J.; Park, C.; Park, Y.N. DNA methyltransferase expression and DNA methylation in human hepatocellular carcinoma and their clinicopathological correlation. Int. J. Mol. Med. 2007, 20, 65-73.
48. Park, H.J.; Yu, E.; Shim, Y.H. DNA methyltransferase expression and DNA hypermethylation in human hepatocellular carcinoma. Cancer Lett. 2006, 233, 271-278.
49. Skvortsova, T.E.; Rykova, E.Y.; Tamkovich, S.N.; Bryzgunova, O.E.; Starikov, A.V.; Kuznetsova, N.P.; Vlassov, V.V.; Laktionov, P.P. Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br. J. Cancer 2006, 94, 1492-1495.
50. Dong, S.M.; Lee, E.J.; Jeon, E.S.; Park, C.K.; Kim, K.M. Progressive methylation during the serrated neoplasia pathway of the colorectum. Mod. Pathol. 2005, 18, 170-178.
51. Ahuja, N.; Li, Q.; Mohan, A.L.; Baylin, S.B.; Issa, J.P. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res. 1998, 58, 5489-5494.
52. Kanai, Y.; Hui, A.M.; Sun, L.; Ushijima, S.; Sakamoto, M.; Tsuda, H.; Hirohashi, S. DNA hypermethylation at the D17S5 locus and reduced HIC-1 mRNA expression are associated with hepatocarcinogenesis. Hepatology 1999, 29, 703-709.
53. Kanai, Y.; Ushijima, S.; Ochiai, A.; Eguchi, K.; Hui, A.; Hirohashi, S. DNA hypermethylation at the D17S5 locus is associated with gastric carcinogenesis. Cancer Lett. 1998, 122, 135-141.
54. Nosho, K.; Irahara, N.; Shima, K.; Kure, S.; Kirkner, G.J.; Schernhammer, E.S.; Hazra, A.; Hunter, D.J.; Quackenbush, J.; Spiegelman, D.; et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One 2008, 3. doi:10.1371/journal.pone.0003698.
55. Tsuji, N.; Furuse, K.; Asanuma, K.; Furuya, M.; Kondoh, K.; Kamagata, C.; Sasaki, M.; Kobayashi, D.; Yagihashi, A.; Takahashi, H.; Watanabe, N. Mutations of the p53 gene and loss of heterozygosity at chromosome 17p13.1 are associated with increased survivin expression in breast cancer. Breast Cancer Res. Treat. 2004, 87, 23-31.
56. Wales, M.M.; Biel, M.A.; el Deiry, W.; Nelkin, B.D.; Issa, J.P.; Cavenee, W.K.; Kuerbitz, S.J.; Baylin, S.B. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat. Med. 1995, 1, 570-577.
57. Zhang, B.; Chambers, K.J.; Leprince, D.; Faller, D.V.; Wang, S. Requirement for chromatin-remodeling complex in novel tumor suppressor HIC1-mediated transcriptional repression and growth control. Oncogene 2009, 28, 651-661.
58. Zhang, W.; Zeng, X.; Briggs, K.J.; Beaty, R.; Simons, B.; Chiu Yen, R.W.; Tyler, M.A.; Tsai, H.C.; Ye, Y.; Gesell, G.S.; et al. A potential tumor suppressor role for Hic1 in breast cancer through transcriptional repression of ephrin-A1. Oncogene 2010, 29, 2467-2476.
59. Zhang, B.; Faller, D.V.; Wang, S. Hic1 regulates tumor cell responses to endocrine therapies. Mol. Endocrinol. 2009, 23, 2075-2085.
60. Nicoll, G.; Crichton, D.N.; McDowell, H.E.; Kernohan, N.; Hupp, T.R.; Thompson, A.M. Expression of the Hypermethylated in Cancer gene (HIC-1) is associated with good outcome in human breast cancer. Br. J. Cancer 2001, 85, 1878-1882.